- Dr. Reddy's to launch generic Prevacid
- New P&G initiative may create clash of the OTC titans
- FDA's new video addresses fracture risk when using PPIs
- New alliance will crack down on adulterated products touting dietary supplement claims
- Takeda: Dexilant, Prevacid have less inhibiting effects on Plavix's efficacy than counterparts
MUMBAI, India — The Food and Drug Administration has approved a drug made by Sun Pharmaceutical Industries for ulcers, Sun said.
Sun announced the approval of lansoprazole delayed-release capsules in the 15-mg and 30-mg strengths.
The drug is a generic version of Takeda's Prevacid delayed-release capsules, which are used for treatment lasting up to four weeks for healing and symptom relief of active duodenal ulcers.
Various versions of the drug have annual sales of about $430 million per year, according to Sun.